Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Express Scripts
Medtronic
Moodys
McKesson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Necitumumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Necitumumab: Sponsors, patents, clinical trial progress

Necitumumab is an investigational drug.

There have been 17 clinical trials for Necitumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Colorectal Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, PPD, and Parexel.

There are twenty-one US patents protecting this investigational drug and six hundred and forty-four international patents.

Recent Clinical Trials for Necitumumab
TitleSponsorPhase
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)AstraZenecaPhase 2
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001Eli Lilly and CompanyPhase 2
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001Montefiore Medical CenterPhase 2

See all Necitumumab clinical trials

Clinical Trial Summary for Necitumumab

Top disease conditions for Necitumumab
Top clinical trial sponsors for Necitumumab

See all Necitumumab clinical trials

US Patents for Necitumumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Necitumumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Necitumumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Necitumumab   Start Trial Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. (Menlo Park, CA)   Start Trial
Necitumumab   Start Trial Mesalamine for the treatment of cancer Cipla Limited (Mumbai, IN)   Start Trial
Necitumumab   Start Trial Heterocyclic compound and pharmaceutical composition comprising same BEYONDBIO INC. (Daejeon, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Necitumumab

Drugname Country Document Number Estimated Expiration Related US Patent
Necitumumab Canada 2900764 2033-02-08   Start Trial
Necitumumab European Patent Office 2954056 2033-02-08   Start Trial
Necitumumab Hong Kong 1218930 2033-02-08   Start Trial
Necitumumab Japan 2016509014 2033-02-08   Start Trial
Necitumumab World Intellectual Property Organization (WIPO) 2014124326 2033-02-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
AstraZeneca
Boehringer Ingelheim
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.